Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy
(2) Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF (trifluridine/tipiracil) bevacizumab and capecitabine bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy. 1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorec...
Source: finanznachrichten.de